Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Catherine Margaret Kelly
Sign up to set email alerts
409
Publications
4,818
Citation Statements Received
4,139
Citation Statements Given
How they've been cited
6,759
214
4,566
38
How they cite others
6,364
153
3,966
20
Affiliations
Mater Misericordiae University Hospital
,
Cancer Trials Ireland
Publications
Order By: Most citations
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Cardoso
1
,
Bartlett
2
,
Slaets
3
et al.
2018
Annals of Oncology
Abstract
Show
443
67
370
17
Get access via publisher
Add to collection
Cite
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina
1
,
Miller
2
,
Yardley
3
et al.
2018
JCO
Abstract
Show
580
10
365
2
Get access via publisher
Add to collection
Cite
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
Loibl
1
,
Marmé
2
,
Martín
3
et al.
2021
JCO
Abstract
Show
348
5
301
1
Get access via publisher
Add to collection
Cite
Spatial predictors of immunotherapy response in triple-negative breast cancer
Wang
1
,
Danenberg
2
,
Huang
3
et al.
2023
Nature
Abstract
Show
413
10
272
1
Get access via publisher
Add to collection
Cite
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Kelly
1
,
Juurlink
2
,
Gomes
3
et al.
2010
BMJ
Abstract
Show
452
9
256
2
Get access via publisher
Add to collection
Cite
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
Montemurro
1
,
Delaloge
2
,
Barrios
3
et al.
2020
Annals of Oncology
Abstract
Show
360
6
245
2
Get access via publisher
Add to collection
Cite
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
Gianni
1
,
Huang
2
,
Egle
3
et al.
2022
Annals of Oncology
431
7
232
1
Get access via publisher
Add to collection
Cite
Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Gianni
1
,
Huang
2
,
Egle
3
et al.
2020
Abstract
Show
177
5
152
2
Get access via publisher
Add to collection
Cite
1
2
3
4
5